# The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

> **NCT06357806** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Peg-IFNα-2b
- **DRUG:** NAs

## Key facts

- **NCT ID:** NCT06357806
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2026-10-08
- **Final completion:** 2026-10-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06357806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06357806, "The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06357806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*